Abstract
Non-small cell lung cancer (NSCLC) is the most common malignancy and the leading cause of cancer death worldwide. In this report, we describe a patient with NSCLC who was treated with continuation of Bevacizumab (Bev) beyond progression to first-line Bev-based chemotherapy. The prolonged treatment with Bev by continuing the inhibition of VEGF beyond first-progression has a strong rationale. Nevertheless, few data exist regarding the efficacy and safety of Bev beyond first line of chemotherapy progression in NSCLC patients. Further studies including a large number of patients are needed, in order to select patients who could benefit from this approach.
Keywords:
bevacizumab; chemotherapy; non-small cell lung cancer.
MeSH terms
-
Angiogenesis Inhibitors / administration & dosage
-
Angiogenesis Inhibitors / therapeutic use*
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Bevacizumab / administration & dosage
-
Bevacizumab / therapeutic use*
-
Carcinoma, Non-Small-Cell Lung / diagnosis
-
Carcinoma, Non-Small-Cell Lung / drug therapy*
-
Carcinoma, Non-Small-Cell Lung / pathology*
-
Disease Progression
-
Fatal Outcome
-
Humans
-
Lung Neoplasms / diagnosis
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / pathology*
-
Male
-
Middle Aged
-
Neoplasm Staging
-
Radiography, Thoracic
-
Retreatment
-
Tomography, X-Ray Computed
-
Treatment Outcome
Substances
-
Angiogenesis Inhibitors
-
Antineoplastic Agents
-
Bevacizumab